{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.335","value":"0.15"},{"groupId":"OG001","spread":"0.397","value":"0.14"}]}],"title":"Independent Living"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.300","value":"0.06"},{"groupId":"OG001","spread":"0.296","value":"0.05"}]}],"title":"Relationships"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.319","value":"0.18"},{"groupId":"OG001","spread":"0.270","value":"0.18"}]}],"title":"Mental Health"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.278","value":"0.08"},{"groupId":"OG001","spread":"0.237","value":"0.05"}]}],"title":"Coping"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.373","value":"0.20"},{"groupId":"OG001","spread":"0.395","value":"0.20"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.140","value":"0.03"},{"groupId":"OG001","spread":"0.137","value":"0.00"}]}],"title":"Senses"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.216","value":"0.11"},{"groupId":"OG001","spread":"0.213","value":"0.11"}]}],"title":"AQoL-6D Utility score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).","dispersionType":"Standard Deviation","groups":[{"description":"Participants who completed induction phase entered in the consolidated treatment phase and received thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.","id":"OG000","title":"Thalidomide + Prednisolone [TP Consolidation]"},{"description":"Participants who completed induction phase entered in the consolidated treatment phase and received bortezomib 1.3 mg/m\\^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.","id":"OG001","title":"Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]"}],"paramType":"MEAN","populationDescription":"All treated randomized analysis set was defined as participants in the all enrolled set (participants with non-missing informed consent date,not screen failures) received at least 1 dose of any study drug and randomized to receive consolidation treatment. Here, 'N'(number of participants analyzed) participants who were evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Month 12","title":"Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase","type":"SECONDARY","unitOfMeasure":"units on a scale"}